share_log

BRIEF-Sarepta Therapeutics Says Investigational Gene Therapy SRP-9003 Shows Sustained Expression And Functional Improvements 2

路透社 ·  Mar 19, 2021 06:13
March 18 (Reuters) - Sarepta Therapeutics Inc :
   * SAREPTA THERAPEUTICS’ INVESTIGATIONAL GENE THERAPY SRP-9003 FOR THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2E SHOWS SUSTAINED EXPRESSION AND FUNCTIONAL IMPROVEMENTS 2 YEARS AFTER ADMINISTRATION
   * SAREPTA THERAPEUTICS INC - RESULTS IN BOTH COHORTS CONTINUE TO REINFORCE SAFETY AND TOLERABILITY PROFILE OF SRP-9003

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment